Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with the Agency for Science, Technology and Research (A*STAR) Bioprocessing Technology Institute (BTI) and National University Health System (NUHS), have developed a groundbreaking technology capable of extracting mesenchymal stem cells (MSCs) directly from pure bone marrow – also known as bone marrow aspirate (BMA), a pivotal source of MSCs – without dilution.
Recent Posts
- Stroke Damage Reversed As Stem Cells Regrow the Brain
- Microencapsulated 3D culture of human umbilical cord-derived mesenchymal stem cells enhances their therapeutic effect on intrauterine adhesion Open Access
- ‘My hero’: 9-year-old boy helps father fight cancer with stem cell donation
- CAR NK cell therapy clinical trial puts follicular lymphoma survivor into remission
- Stem cell therapy linked to lower risk of heart failure after a heart attack

